
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4127221</article-id><article-id pub-id-type="doi">10.1155/2014/873010</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Potential Smoothened Inhibitor from Traditional Chinese Medicine against the Disease of Diabetes, Obesity, and Cancer </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0223-1577</contrib-id><name><surname>Chen</surname><given-names>Kuan-Chung</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1465-0330</contrib-id><name><surname>Sun</surname><given-names>Mao-Feng</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hsin-Yi</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Cheng-Chun</given-names></name><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3306-250X</contrib-id><name><surname>Chen</surname><given-names>Calvin Yu-Chian</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref><xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref><xref ref-type="corresp" rid="cor2">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>School of Pharmacy, China Medical University, Taichung 40402, Taiwan</aff><aff id="I2"><sup>2</sup>School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan</aff><aff id="I3"><sup>3</sup>Department of Acupuncture, China Medical University Hospital, Taichung, Taiwan</aff><aff id="I4"><sup>4</sup>Research Center for Chinese Medicine &amp; Acupuncture, China Medical University, Taichung, Taiwan</aff><aff id="I5"><sup>5</sup>Department of Biomedical Informatics, Asia University, Taichung 41354, Taiwan</aff><aff id="I6"><sup>6</sup>School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan</aff><aff id="I7"><sup>7</sup>Human Genetic Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan</aff><author-notes><corresp id="cor1">*Cheng-Chun Lee: <email>leeck@mail.cmu.edu.tw</email> and </corresp><corresp id="cor2">*Calvin Yu-Chian Chen: <email>ycc929@MIT.edu</email></corresp><fn fn-type="other"><p><text><SENT sid="1" pm="."><plain>Academic Editor: Chung Y. </plain></SENT>
<SENT sid="2" pm="."><plain>Hsu </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>1</day><month>7</month><year>2014</year></pub-date><volume>2014</volume><elocation-id>873010</elocation-id><history><date date-type="received"><day>14</day><month>2</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>2</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014 Kuan-Chung Chen et al.</copyright-statement><copyright-year>2014</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="3" pm="."><plain>Nowadays, obesity becomes a serious global problem, which can induce a series of diseases such as type 2 diabetes mellitus, cancer, cardiovascular disease, metabolic syndrome, and stoke. </plain></SENT>
<SENT sid="4" pm="."><plain>For the mechanisms of diseases, the hedgehog signaling pathway plays an important role in body patterning during embryogenesis. </plain></SENT>
<SENT sid="5" pm="."><plain>For this reason, smoothened homologue (Smo) protein had been indicated as the drug target. </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, the small-molecule Smo inhibitor had also been used in oncology clinical trials. </plain></SENT>
<SENT sid="7" pm="."><plain>To improve drug development of TCM compounds, we aim to investigate the potent lead compounds as Smo inhibitor from the TCM compounds in TCM Database@Taiwan. </plain></SENT>
<SENT sid="8" pm="."><plain>The top three TCM compounds, precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid), have displayed higher potent binding affinities than the positive control, LY2940680, in the docking simulation. </plain></SENT>
<SENT sid="9" pm="."><plain>After MD simulations, which can optimize the result of docking simulation and validate the stability of H-bonds between each ligand and Smo protein under dynamic conditions, top three TCM compounds maintain most of interactions with Smo protein, which keep the ligand binding stable in the binding domain. </plain></SENT>
<SENT sid="10" pm="."><plain>Hence, we propose precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid) as potential lead compounds for further study in drug development process with the Smo protein. </plain></SENT>
</text></SecTag></p></abstract></article-meta></front><body><SecTag type="INTRO"><sec id="sec1"><title><text><SENT sid="11" pm="."><plain>1. </plain></SENT>
<SENT sid="12" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="13" pm="."><plain>Nowadays, obesity, which is caused by the body's inability to handle excessive energy intake, becomes a serious global problem. </plain></SENT>
<SENT sid="14" pm="."><plain>It can induce a series of diseases such as type 2 diabetes mellitus, cancer, cardiovascular disease, metabolic syndrome, and stroke [1, 2]. </plain></SENT>
<SENT sid="15" pm="."><plain>In fact, the diseases of diabetes, obesity, and cancer have the dysregulated intracellular signaling and altered metabolic state [3]. </plain></SENT>
<SENT sid="16" pm="."><plain>Nowadays, increasing numbers of distinct mechanisms of diseases have been determined [4–6]. </plain></SENT>
<SENT sid="17" pm="."><plain>According to these mechanisms, increasing numbers of potential target proteins for drug design against each disease have been identified [7, 8]. </plain></SENT>
<SENT sid="18" pm="."><plain>The hedgehog signaling pathway plays an important role in body patterning during embryogenesis [9]. </plain></SENT>
<SENT sid="19" pm="."><plain>Abnormalities in hedgehog signaling pathway can lead to diabetes, obesity, and cancer [10–14]. </plain></SENT>
<SENT sid="20" pm="."><plain>As hedgehog pathway genes encoding patched homologue 1 (Ptch1) and smoothened homologue (Smo), Smo protein had been indicated as the drug target, and the small-molecule Smo inhibitor had been used in oncology clinical trials [15–18]. </plain></SENT>
</text></p><p><text><SENT sid="21" pm="."><plain>Many in silico researches had indicated that compounds extracted from traditional Chinese medicine (TCM) can be used as potential lead compounds for many different diseases [19], such as cancer [20–23], diabetes [24], inflammation [25], influenza [26], metabolic syndrome [27, 28], stroke [29–32], viral infection [33], and some other diseases [34, 35]. </plain></SENT>
<SENT sid="22" pm="."><plain>To improve drug development of TCM compounds, we aim to investigate the potent lead compounds as Smo inhibitor from the TCM compounds in TCM Database@Taiwan [36]. </plain></SENT>
<SENT sid="23" pm="."><plain>As structural disordered residues in the protein may lead to the side effect and influence the ligand to bind with target protein [37, 38], the disordered residues of Smo protein were predicted before virtual screening. </plain></SENT>
<SENT sid="24" pm="."><plain>After virtual screening of the TCM compounds, as the interactions between protein and ligand in the docking simulation may not be stable under dynamic conditions, the molecular dynamics (MD) simulations were performed to validate the stability of those interactions. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="sec2"><title><text><SENT sid="25" pm="."><plain>2. </plain></SENT>
<SENT sid="26" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="sec2.1"><title><text><SENT sid="27" pm="."><plain>2.1. </plain></SENT>
<SENT sid="28" pm="."><plain>Data Collection </plain></SENT>
</text></title><p><text><SENT sid="29" pm="."><plain>The X-ray crystallography structure of the human smoothened receptor (Smo) was obtained from RCSB Protein Data Bank with PDB ID: 4JKV [39]. </plain></SENT>
<SENT sid="30" pm="."><plain>PONDR-Fit [40] protocol was employed to predict the disordered amino acids for the sequence of Smo protein from Swiss-Prot (UniProtKB: Q99835). </plain></SENT>
<SENT sid="31" pm="."><plain>For the protein preparation, Prepare Protein module in Discovery Studio 2.5 (DS2.5) was employed to protonate the final structure of protein with Chemistry at HARvard Macromolecular Mechanics (CHARMM) force field [41] and remove crystal water. </plain></SENT>
<SENT sid="32" pm="."><plain>The binding site for virtual screening was defined by the volume of the cocrystallized antitumor agent, LY2940680. </plain></SENT>
<SENT sid="33" pm="."><plain>Prepare Ligand module in DS2.5 was employed to protonate the final structure of TCM compounds from TCM Database@Taiwan [36], and Lipinski's Rule of Five [42] was applied to filter the TCM compounds after virtual screening. </plain></SENT>
</text></p></sec><sec id="sec2.2"><title><text><SENT sid="34" pm="."><plain>2.2. </plain></SENT>
<SENT sid="35" pm="."><plain>Docking Simulation </plain></SENT>
</text></title><p><text><SENT sid="36" pm="."><plain>LigandFit protocol [43] in DS 2.5 was employed to virtually screen the TCM compounds by docking ligands into the binding site using a shape filter and Monte-Carlo ligand conformation generation. </plain></SENT>
<SENT sid="37" pm="."><plain>The result of docking was then optionally minimized with CHARMM force field [41] and evaluated with Dock Score energy function as follows: (1)Dock  Score=−(ligand receptor interaction energy   +  ligand internal energy). </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>The clustering of saved docking pose was performed to reject the similar poses. </plain></SENT>
</text></p></sec><sec id="sec2.3"><title><text><SENT sid="39" pm="."><plain>2.3. </plain></SENT>
<SENT sid="40" pm="."><plain>Molecular Dynamics (MD) Simulation </plain></SENT>
</text></title><p><text><SENT sid="41" pm="."><plain>Gromacs [44] was employed to simulate each protein-ligand complex under dynamic conditions using classical molecular dynamics theory. </plain></SENT>
<SENT sid="42" pm="."><plain>The pdb2gmx protocol of Gromacs and SwissParam program [45] were employed to provide topology and parameters for Smo protein with charmm27 force field and each ligand, respectively. </plain></SENT>
<SENT sid="43" pm="."><plain>The Gromacs program sets the dimensions of the cubic box based upon setting the box edge approx 12 Å from the molecules periphery and solvated using TIP3P water model. </plain></SENT>
<SENT sid="44" pm="."><plain>Steepest descent [46] is one of the common algorithms for minimization. </plain></SENT>
<SENT sid="45" pm="."><plain>For this algorithm, new positions are calculated by the equation as follows: (2)rn+1=rn+Fnmax⁡(|Fn|)hnIf  Vn+1&lt;Vn,  rn+1  accepted  and  hn+1=1.2hnotherwise,rn+1  rejected  and  hn=0.2hn, where r is the vector of all 3N coordinates, h n is the maximum displacement and initial h 0 is given in unit of 0.01 nm, and F n is the force or the negative gradient of the potential V. </plain></SENT>
</text></p><p><text><SENT sid="46" pm="."><plain>The algorithm stops when max⁡(|F n|) &lt; ε or complete the maximum number of iterations defined in the protocol. </plain></SENT>
<SENT sid="47" pm="."><plain>After a steepest descent minimization with a maximum of 5,000 steps was employed to remove bad van der Waals contacts, it created a neutral system using 0.145 M NaCl model. </plain></SENT>
<SENT sid="48" pm="."><plain>Then another steepest descent minimization with a maximum of 5,000 steps was employed to remove bad van der Waals contacts. </plain></SENT>
<SENT sid="49" pm="."><plain>For the equilibration, the position-restrained molecular dynamics with the Linear Constraint algorithm for all bonds was performed with NVT equilibration, Berendsen weak thermal coupling method, and Particle Mesh Ewald method. </plain></SENT>
<SENT sid="50" pm="."><plain>The Berendsen weak thermal coupling method mimics with first-order kinetics an external heat bath with given temperature 300 K and slowly corrected the temperature deviation of the system by the equation as follows: (3)∂T∂t=T0−Tτ, where T 0 is given temperature 300 K and τ is a time constant in unit of 0.1 ps. </plain></SENT>
</text></p><p><text><SENT sid="51" pm="."><plain>The MD program was then employed to simulate a total of 5000 ps production simulation with time step in unit of 2 fs under Particle Mesh Ewald (PME) option and NPT ensembles. </plain></SENT>
<SENT sid="52" pm="."><plain>A series of protocols in Gromacs was employed to analyze the MD trajectories. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS,DISCUSS"><sec id="sec3"><title><text><SENT sid="53" pm="."><plain>3. </plain></SENT>
<SENT sid="54" pm="."><plain>Results and Discussion </plain></SENT>
</text></title><sec id="sec3.1"><title><text><SENT sid="55" pm="."><plain>3.1. </plain></SENT>
<SENT sid="56" pm="."><plain>Disordered Protein Prediction </plain></SENT>
</text></title><p><text><SENT sid="57" pm="."><plain>The disordered disposition for the sequence of Smo protein from Swiss-Prot (UniProtKB: Q99835) predicted by PONDR-Fit was illustrated in Figure 1. </plain></SENT>
<SENT sid="58" pm="."><plain>As the residues in the binding domain do not lie in the disordered region, the binding domain of Smo protein has a stable structure in protein folding. </plain></SENT>
</text></p></sec><sec id="sec3.2"><title><text><SENT sid="59" pm="."><plain>3.2. </plain></SENT>
<SENT sid="60" pm="."><plain>Docking Simulation </plain></SENT>
</text></title><p><text><SENT sid="61" pm="."><plain>Before virtual screening, the cocrystallized antitumor agent, LY2940680, had been redocked by LigandFit protocol into the binding site defined by the volume of LY2940680 (Figure 2(a)) to validate the accuracy of LigandFit protocol. </plain></SENT>
<SENT sid="62" pm="."><plain>The Root-mean-square deviation value between crystallized structure and docking pose of LY2940680 is 0.5106 Å (Figure 2(b)). </plain></SENT>
<SENT sid="63" pm="."><plain>After virtual screening, the chemical scaffold top TCM compounds ranked by Dock Score [43] and LY2940680 are illustrated in Figure 3. </plain></SENT>
<SENT sid="64" pm="."><plain>The scoring function of Dock Score indicates that the top three TCM compounds have higher binding affinities than LY2940680. </plain></SENT>
<SENT sid="65" pm="."><plain>The top three TCM compounds, precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid), are extracted from Abrus precatorius L., Rosmarinus officinalis L., and Ardisia japonica, respectively. </plain></SENT>
<SENT sid="66" pm="."><plain>According to the docking poses in Figure 4, for positive control, LY2940680, there exists a π interaction with residue Phe484 and hydrogen bonds (H-bonds) with residues Asn219 and Arg400. </plain></SENT>
<SENT sid="67" pm="."><plain>Precatorine has π interactions with residues Tyr394, Arg400, Phe484, and H-bonds with residue Lys395. </plain></SENT>
<SENT sid="68" pm="."><plain>Labiatic acid has a π interaction with residue Phe484 and H-bonds with residues Tyr207, Lys395, and Arg400. </plain></SENT>
<SENT sid="69" pm="."><plain>The top 3 compounds have π interactions with residues Tyr394, Arg400, Phe484, and H-bonds with resides Tyr394, Lys395, His470, and Asn521. </plain></SENT>
<SENT sid="70" pm="."><plain>The docking poses displayed in Figure 4 indicate that each compound has a π interaction with residue Phe484 and interaction with common residues Lys395 and Arg400. </plain></SENT>
<SENT sid="71" pm="."><plain>Those interactions stabilize each compound in the binding domain of Smo protein. </plain></SENT>
</text></p></sec><sec id="sec3.3"><title><text><SENT sid="72" pm="."><plain>3.3. </plain></SENT>
<SENT sid="73" pm="."><plain>Molecular Dynamics Simulation </plain></SENT>
</text></title><p><text><SENT sid="74" pm="."><plain>The docking simulation performed by LigandFit protocol docks compounds into binding site using a shape-based docking. </plain></SENT>
<SENT sid="75" pm="."><plain>Although the Monte-Carlo techniques had been employed to simulate the flexible compound by generating sets of compound conformations, the structure of target protein is a rigid body of Smo protein from the crystal structure. </plain></SENT>
<SENT sid="76" pm="."><plain>As the interactions between protein and ligand in the docking simulation may not be stable under dynamic conditions, the molecular dynamics (MD) simulations were performed to validate the stability of those interactions. </plain></SENT>
<SENT sid="77" pm="."><plain>The root-mean-square deviations (RMSDs) for each protein and ligand were displayed in Figure 5. </plain></SENT>
<SENT sid="78" pm="."><plain>They indicate the atomic fluctuations during MD simulation for each protein and ligand. Figure 5 shows that the atomic fluctuations of each complex tend to be stable after 4700 ps of MD simulation. </plain></SENT>
<SENT sid="79" pm="."><plain>The variations of total energy for each complex during 5000 ps of MD simulation were illustrated in Figure 6, which indicate that Smo protein docking with the top three TCM compounds has similar variation of total energy, and there is no significant change of total energy for each complex during 5000 ps of MD simulation. </plain></SENT>
<SENT sid="80" pm="."><plain>The variation of radius of gyration and mean square displacement (MSD) for proteins in each complex during 5000 ps of MD simulation was illustrated in Figures 7 and 8, respectively. </plain></SENT>
<SENT sid="81" pm="."><plain>They indicate that Smo protein docking with the top three TCM compounds has similar compactness and diffusion constant under dynamic conditions as LY2940680. </plain></SENT>
<SENT sid="82" pm="."><plain>The variation of solvent accessible surface area in Figure 9 can also be used to discuss the effect of each ligand for the Smo protein after docking. </plain></SENT>
<SENT sid="83" pm="."><plain>In Figure 9, it can be seen clearly that the Smo protein in each complex has similar solvent accessible surface area when the RMSDs tend to be stable after 4700 ps of MD simulation. </plain></SENT>
<SENT sid="84" pm="."><plain>The smallest distance between residue pairs for Smo protein in each complex illustrated in Figure 10 also has similar distance matrices. </plain></SENT>
<SENT sid="85" pm="."><plain>They indicate that the top three TCM compounds may cause similar influence for Smo protein as LY2940680. </plain></SENT>
</text></p><p><text><SENT sid="86" pm="."><plain>For the MD simulation, the representative structures of each complex under dynamic conditions were identified by the cluster analysis with a RMSD cutoff of 0.105 nm. </plain></SENT>
<SENT sid="87" pm="."><plain>According to the RMSD values and graphical depiction of the clusters for Smo protein complexes with LY2940680, precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid) illustrated in Figure 11, the docking poses of the representative structures for Smo protein complex with LY2940680 and the top three TCM compounds were illustrated in Figure 12. </plain></SENT>
<SENT sid="88" pm="."><plain>For LY2940680, there exist the stable H-bonds with residues Asn219 and Arg400 under dynamic conditions. </plain></SENT>
<SENT sid="89" pm="."><plain>In addition, it forms an H-bond with Tyr394 after MD simulation. </plain></SENT>
<SENT sid="90" pm="."><plain>Precatorine has stable π interactions with residue Phe484 and H-bonds with Lys395. </plain></SENT>
<SENT sid="91" pm="."><plain>After MD simulation, it forms an H-bond with residue Asn219. </plain></SENT>
<SENT sid="92" pm="."><plain>Labiatic acid has stable H-bonds with residues Tyr207, Lys395 and forms the H-bonds with residues Asp384, Gln477, and Glu518. </plain></SENT>
<SENT sid="93" pm="."><plain>The top 3 TCM compounds have stable π interactions with residue Phe484 and H-bonds with residue Lys395. </plain></SENT>
<SENT sid="94" pm="."><plain>Moreover, the interaction with residue Arg400 was changed from π interaction to H-bond and forms the H-bonds with residues Tyr207 and Arg285 after MD simulation. </plain></SENT>
</text></p><p><text><SENT sid="95" pm="."><plain>To analyze the variation of H-bonds for key residues in each protein-ligand complex, the H-bond occupancy for key residues of Smo protein with top three candidates and LY2940680 overall 5000 ps of MD simulation was listed in Table 1, and the distance variations of each H-bond were displayed in Figure 13. </plain></SENT>
<SENT sid="96" pm="."><plain>They indicate that the H-bonds between LY2940680 and residues Asn219, Tyr394, Arg400 were stabilized over 5000 ps of MD simulation. </plain></SENT>
<SENT sid="97" pm="."><plain>In addition, the H-bonds between top three TCM compounds and residues mentioned above were also stabilized. </plain></SENT>
<SENT sid="98" pm="."><plain>Comparing to docking poses between docking simulation (Figure 4) and MD simulation (Figure 12), LY2940680 and the top three TCM compounds maintain most of interactions with Smo protein, which keep the ligand binding stable in the binding domain. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="CONCL"><sec id="sec4"><title><text><SENT sid="99" pm="."><plain>4. </plain></SENT>
<SENT sid="100" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="101" pm="."><plain>This study aims to investigate the potent TCM candidates for Smo protein. </plain></SENT>
<SENT sid="102" pm="."><plain>The top three TCM compounds, precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid), have displayed higher potent binding affinities than the positive control, LY2940680, in the docking simulation. </plain></SENT>
<SENT sid="103" pm="."><plain>The docking poses of top three TCM compounds have similar π interaction with residue Phe484 and interaction with common residues Lys395 and Arg400. </plain></SENT>
<SENT sid="104" pm="."><plain>The MD simulations are employed to optimize the result of docking simulation and validate the stability of H-bonds between each ligand and Smo protein under dynamic conditions. </plain></SENT>
<SENT sid="105" pm="."><plain>For the MD simulation, the top three TCM compounds maintain most of interactions with Smo protein, which keep the ligand binding stable in the binding domain. </plain></SENT>
<SENT sid="106" pm="."><plain>Hence, we propose precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid) as potential lead compounds for further study in drug development process with the Smo protein. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="107" pm="."><plain>The research was supported by grants from the National Science Council of Taiwan (NSC102-2325-B039-001 and NSC102-2221-E-468-027-), Asia University (ASIA100-CMU-2, ASIA101-CMU-2, and 102-ASIA-07), China Medical University (CMU99-TC-24, and CMU102-BC-3), and China Medical University Hospital (DMR-102-001, DMR-102-051, DMR-103-058, DMR-103-001, and DMR-103-096). </plain></SENT>
<SENT sid="108" pm="."><plain>This study is also supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004), Taiwan Department of Health Cancer Research Center of Excellence (MOHW103-TD-B-111-03), and CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="COMP_INT"><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declared that there is no conflict of interests.</p></sec></SecTag><SecTag type="AUTH_CONT"><sec><title>Authors' Contribution</title><p>Kuan-Chung Chen, Mao-Feng Sun, and Hsin-Yi Chen contributed equally to this work.</p></sec></SecTag><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="109" pm="?"><plain>1Jauch-CharaKOltmannsKMObesity—a neuropsychological disease? </plain></SENT>
<SENT sid="110" pm="."><plain>Systematic review and neuropsychological modelProgress in Neurobiology20141148410124394671 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="111" pm="."><plain>2GuriAJHontecillasRBassaganya-RieraJPeroxisome proliferator-activated receptors: bridging metabolic syndrome with molecular nutritionClinical Nutrition20062568718852-s2.0-3375100641217052808 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="112" pm="."><plain>3TeperinoRAmannSBayerMHedgehog partial agonism drives warburg-like metabolism in muscle and brown fatCell201215124144262-s2.0-8486753663923063129 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="113" pm="."><plain>4JiangYLiXYangWPKM2 regulates chromosome segregation and mitosis progression of tumor cellsMolecular Cell2014531758724316223 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="114" pm="."><plain>5ChangY-MVelmuruganBKKuoW-WInhibitory effect of alpinate Oxyphyllae fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cellsBioMedicine2013341481522-s2.0-84878732300 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="115" pm="."><plain>6LeungYMWongKLChenSWDown-regulation of voltage-gated Ca2+ channels in Ca2+ store-depleted rat insulinoma RINm5F cellsBioMedicine2013331301392-s2.0-84881370670 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="116" pm="."><plain>7LeissringMAMalitoEHedouinSDesigned inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulinPLoS ONE2010552-s2.0-77956274306e10504 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="117" pm="."><plain>8JaoC-LHuangS-LHsuK-CAngiotensin I-converting enzyme inhibitory peptides: inhibition mode, bioavailability, and antihypertensive effectsBioMedicine2012241301362-s2.0-84871621268 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="118" pm="."><plain>9McMahonAPInghamPWTabinCJDevelopmental roles and clinical significance of Hedgehog signalingCurrent Topics in Developmental Biology20035311142-s2.0-000245256912509125 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="119" pm="."><plain>10ScalesSJde SauvageFJMechanisms of Hedgehog pathway activation in cancer and implications for therapyTrends in Pharmacological Sciences20093063033122-s2.0-6765028958419443052 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="120" pm="."><plain>11SekulicAMangoldARNorthfeltDWLorussoPMAdvanced basal cell carcinoma of the skin: targeting the Hedgehog pathwayCurrent Opinion in Oncology20132532182232-s2.0-8487629541223493193 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="121" pm="."><plain>12McMillanRMatsuiWMolecular pathways: the hedgehog signaling pathway in cancerClinical Cancer Research20121818488348882-s2.0-8486636599722718857 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="122" pm="."><plain>13ChennaVHuCKhanSRSynthesis and cytotoxicity studies of Hedgehog enzyme inhibitors SANT-1 and GANT-61 as anticancer agentsJournal of Environmental Science and Health A: Toxic/Hazardous Substances and Environmental Engineering201449664164724521409 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="123" pm="."><plain>14AmakyeDJaganiZDorschMUnraveling the therapeutic potential of the Hedgehog pathway in cancerNature Medicine2013191114101422 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="124" pm="."><plain>15Von HoffDDLoRussoPMRudinCMInhibition of the hedgehog pathway in advanced basal-cell carcinomaThe New England Journal of Medicine200936112116411722-s2.0-7034923873319726763 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="125" pm="."><plain>16ProctorAEThompsonLAO'BryantCLVismodegib: an inhibitor of the hedgehog signaling pathway in the treatment of basal cell carcinomaThe Annals of Pharmacotherapy20144819910624259609 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="126" pm="."><plain>17XinMZhangLTangFDesign, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitorsBioorganic &amp; Medicinal Chemistry20142241429144024486203 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="127" pm="."><plain>18KunstfeldRSmoothened inhibitors in the treatment of advanced basal cell carcinomasCurrent Opinion in Oncology201426218419524469022 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="128" pm="."><plain>19ChenCYA novel integrated framework and improved methodology of computer-aided drug designCurrent Topics in Medicinal Chemistry20131399659882-s2.0-8487877518723651478 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="129" pm="."><plain>20ChenCYChenCYCInsights into designing the dual-targeted HER2/HSP90 inhibitorsJournal of Molecular Graphics and Modelling201029121312-s2.0-7795577255220471294 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="130" pm="."><plain>21YangSCChangSSChenHYChenCYCIdentification of potent EGFR inhibitors from TCM Database@TaiwanPLoS Computational Biology20117102-s2.0-80055077153e1002189 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="131" pm="."><plain>22TsouYAChenKCLinHCChangSSChenCYCUroporphyrinogen decarboxylase as a potential target for specific components of Traditional Chinese Medicine: a virtual screening and molecular dynamics studyPLoS ONE20127112-s2.0-84870550823e50087 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="132" pm="."><plain>23TsouYAChenKCChangSSWenYRChenCYA possible strategy against head and neck cancer: in silico investigation of three-in-one inhibitorsJournal of Biomolecular Structure and Dynamics201331121358136923140436 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="133" pm="."><plain>24ChenKCChangSSTsaiFJChenCYHan ethnicity-specific type 2 diabetic treatment from Traditional Chinese Medicine?Journal of Biomolecular Structure and Dynamics201331111219123523146021 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="134" pm="."><plain>25ChenKCSunMFYangSCInvestigation into potent inflammation inhibitors from Traditional Chinese MedicineChemical Biology and Drug Design20117846796882-s2.0-8005261917421801310 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="135" pm="?"><plain>26ChangSSHuangHJChenCYTwo birds with one stone? </plain></SENT>
<SENT sid="136" pm="."><plain>Possible dual-targeting H1N1 inhibitors from Traditional Chinese MedicinePLoS Computational Biology20117122-s2.0-84855282742e1002315 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="137" pm="."><plain>27HuangHJLeeKJYuHWChenHTsaiFChenCYA novel strategy for designing the selective PPAR agonist by the “sum of activity” modelJournal of Biomolecular Structure and Dynamics20102821872002-s2.0-7795730371020645652 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="138" pm="."><plain>28ChenKCChangSSHuangHJLinTWuYChenCYThree-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from Traditional Chinese MedicineJournal of Biomolecular Structure and Dynamics20123066626832-s2.0-8487118181422731403 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="139" pm="?"><plain>29ChenK-CChenCYCStroke prevention by Traditional Chinese Medicine? </plain></SENT>
<SENT sid="140" pm="."><plain>A genetic algorithm, support vector machine and molecular dynamics approachSoft Matter201178400140082-s2.0-79953746295 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="141" pm="."><plain>30ChenKCChangKWChenHYChenCYCTraditional Chinese Medicine, a solution for reducing dual stroke risk factors at once?Molecular BioSystems201179271127192-s2.0-8005176068421796302 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="142" pm="."><plain>31ChangTTChenKCChangKW In silico pharmacology suggests ginger extracts may reduce stroke risksMolecular BioSystems201179270227102-s2.0-8005176719521776525 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="143" pm="."><plain>32IeongtouWChangSSWuDMolecular level activation insights from a NR2A/NR2B agonistJournal of Biomolecular Structure and Dynamics201432568369323600691 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="144" pm="."><plain>33HuangHJJianYRChenCYTraditional Chinese Medicine application in HIV: an in silico studyJournal of Biomolecular Structure and Dynamics201432111223252879 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="145" pm="."><plain>34TouWIChangSSLeeCCChenCYDrug design for neuropathic pain regulation from Traditional Chinese MedicineScientific Reports20133p. </plain></SENT>
<SENT sid="146" pm="."><plain>8442-s2.0-84880533871 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="147" pm="."><plain>35ChenKCJianYRSunMFChangTTLeeCCChenCYInvestigation of silent information regulator 1 (Sirt1) agonists from Traditional Chinese MedicineJournal of Biomolecular Structure and Dynamics201331111207121823075283 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="148" pm="."><plain>36ChenCYCTCM Database@Taiwan: the world’s largest Traditional Chinese Medicine database for drug screening in silico PLoS ONE2011612-s2.0-79251561193e15939 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="149" pm="."><plain>37TouWIChenCYMay disordered protein cause serious drug side effect?Drug Discovery Today201419436737224184432 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="150" pm="."><plain>38ChenCYCTouWIHow to design a drug for the disordered proteins?Drug Discovery Today20131819-209109152-s2.0-8487774019123643489 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="151" pm="."><plain>39WangCWuHKatritchVStructure of the human smoothened receptor bound to an antitumour agentNature201349774493383432-s2.0-8487811210623636324 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="152" pm="."><plain>40XueBDunbrackRLWilliamsRWDunkerAKUverskyVNPONDR-FIT: a meta-predictor of intrinsically disordered amino acidsBiochimica et Biophysica Acta—Proteins and Proteomics20101804499610102-s2.0-76849087968 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="153" pm="."><plain>41BrooksBRBruccoleriREOlafsonBDStatesDJSwaminathanSKarplusMCHARMM: a program for macromolecular energy minimization and dynamics calculationsJournal of Computational Chemistry198342187217 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="154" pm="."><plain>42LipinskiCALombardoFDominyBWFeeneyPJExperimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews2001461–33262-s2.0-003528977911259830 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="155" pm="."><plain>43VenkatachalamCMJiangXOldfieldTWaldmanMLigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sitesJournal of Molecular Graphics and Modelling20032142893072-s2.0-003721210212479928 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="156" pm="."><plain>44HessBKutznerCvan der SpoelDLindahlEGRGMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulationJournal of Chemical Theory and Computation2008434354472-s2.0-4624909255426620784 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="157" pm="."><plain>45ZoeteVCuendetMAGrosdidierAMichielinOSwissParam: a fast force field generation tool for small organic moleculesJournal of Computational Chemistry20113211235923682-s2.0-7995884170321541964 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="158" pm="."><plain>46FletcherROptimization1969New York, NY, USAAcademic Press </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="159" pm="."><plain>Disordered disposition predicted by PONDR-Fit. </plain></SENT>
<SENT sid="160" pm="."><plain>Sequence alignment with disordered residues (yellow regions) and residues in the binding domain (magenta regions). </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-873010.001"/></fig></SecTag><SecTag type="FIG"><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="161" pm="."><plain>(a) Binding site of Smo protein defined as the volume of LY2940680. </plain></SENT>
<SENT sid="162" pm="."><plain>(b) Root-mean-square deviation value between crystallized structure (orange) and docking pose (green) of LY2940680. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-873010.002"/></fig></SecTag><SecTag type="FIG"><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p><text><SENT sid="163" pm="."><plain>Chemical scaffold of controls and top three TCM candidates with their scoring function and sources. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-873010.003"/></fig></SecTag><SecTag type="FIG"><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p><text><SENT sid="164" pm="."><plain>Docking pose of Smo protein complexes with (a) LY2940680, (b) precatorine, (c) labiatic acid, and (d) 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid). </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-873010.004"/></fig></SecTag><SecTag type="FIG"><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p><text><SENT sid="165" pm="."><plain>Root-mean-square deviations in units of nm for protein (a) and ligand (b) over 5000 ps of MD simulation in Smo protein complexes with LY2940680, precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid). </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-873010.005"/></fig></SecTag><SecTag type="FIG"><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p><text><SENT sid="166" pm="."><plain>Total energy for complex over 5000 ps of MD simulation in Smo protein complexes with LY2940680, precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid). </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-873010.006"/></fig></SecTag><SecTag type="FIG"><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p><text><SENT sid="167" pm="."><plain>Radii of gyration for protein over 5000 ps of MD simulation in Smo protein complexes with LY2940680, precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid). </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-873010.007"/></fig></SecTag><SecTag type="FIG"><fig id="fig8" orientation="portrait" position="float"><label>Figure 8</label><caption><p><text><SENT sid="168" pm="."><plain>Mean square displacement (MSD) for protein over 5000 ps of MD simulation in Smo protein complexes with LY2940680, precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid). </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-873010.008"/></fig></SecTag><SecTag type="FIG"><fig id="fig9" orientation="portrait" position="float"><label>Figure 9</label><caption><p><text><SENT sid="169" pm="."><plain>Variation of (a) total solvent accessible surface area, (b) hydrophobic surface area, and (c) hydrophilic surface area over 5000 ps of MD simulation for Smo protein complexes with LY2940680, precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid). </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-873010.009"/></fig></SecTag><SecTag type="FIG"><fig id="fig10" orientation="portrait" position="float"><label>Figure 10</label><caption><p><text><SENT sid="170" pm="."><plain>Smallest distance between residue pairs for protein over 5000 ps of MD simulation in Smo protein complexes with LY2940680, precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid). </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-873010.010"/></fig></SecTag><SecTag type="FIG"><fig id="fig11" orientation="portrait" position="float"><label>Figure 11</label><caption><p><text><SENT sid="171" pm="."><plain>Root-mean-square deviation value (upper left half) and graphical depiction of the clusters with cutoff 0.105 nm (lower right half) for Smo protein complexes with LY2940680, precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid). </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-873010.011"/></fig></SecTag><SecTag type="FIG"><fig id="fig12" orientation="portrait" position="float"><label>Figure 12</label><caption><p><text><SENT sid="172" pm="."><plain>Docking poses of middle RMSD structure in the major cluster for Smo protein complexes with LY2940680, precatorine, labiatic acid, and 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid). </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-873010.012"/></fig></SecTag><SecTag type="FIG"><fig id="fig13" orientation="portrait" position="float"><label>Figure 13</label><caption><p><text><SENT sid="173" pm="."><plain>Distances of hydrogen bonds with common residues during 5000 ps of MD simulation. </plain></SENT>
</text></p></caption><graphic xlink:href="BMRI2014-873010.013"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="174" pm="."><plain>H-bond occupancy for key residues of Smo protein with top three candidates and LY2940680 overall 5000 ps of molecular dynamics simulation. </plain></SENT>
</text></p></caption><table-wrap-foot><fn><p>H-bond occupancy cutoff: 0.3 nm.</p></fn><fn><p>
Top 3: 2,2′-[benzene-1,4-diylbis(methanediyloxybenzene-4,1-diyl)]bis(oxoacetic acid).</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
